Results 211 to 220 of about 186,761 (273)

Precision immunotherapy for breast cancer: from biomarkers to clinical practice. [PDF]

Cancer Biol Med
Mei J, Yang K, Zhang X, Huang X, Yin Y.
europepmc   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. [PDF]

Eur J Cardiothorac Surg
Tsuboi M, Wakelee H, Garassino MC, Gao S, Luft A, Chen KN, Spicer JD, Zhu Y, Saji H, Okada M, Vanakesa T, Chen H, Zhao G, Ikeda N, Jones DR, Weksler B, Huang CS, Jensen E, Keller SM, Samkari A, Liberman M.   +20 more
europepmc   +1 more source

‘BJUI Clinical Dilemma’: Recurrent high‐grade non‐muscle‐invasive bladder cancer in 2026

BJU International, EarlyView.
Vignesh T. Packiam, Peter C. Black, James W. F. Catto, Saum Ghodoussipour, Max Kates, Ashish M. Kamat, Yair Lotan, Michael A. O’Donnell, Jeremy Y. C. Teoh, George N. Thalmann, Stephen B. Williams   +10 more
wiley   +1 more source

Recurrent Immune Checkpoint Inhibitor Hepatitis With Pembrolizumab Cessation: A Stubborn Case of Delayed-Onset, Steroid-Refractory Hepatotoxicity. [PDF]

ACG Case Rep J
Ladetto A, Gildea DT, Shenoy A.
europepmc   +1 more source

Human IDO2 exhibits unique binding affinities distinct to those of human IDO1

The FEBS Journal, EarlyView.
Although indoleamine 2,3‐dioxygenase 2 (IDO2) is highly homologous to IDO1, it displays markedly lower catalytic activity. We found that IDO2 binds L‐tryptophan (L‐Trp) in a flipped orientation stabilized by the IDO2‐specific residue His143. Replacement of His143 with the IDO1‐equivalent tyrosine restored an IDO1‐like binding mode and increased ...
Shunsuke Nogi, Ayumu Takahashi, So Murakami, Nami Adachi, Tina Fujimoto, Yohta Fukuda, Taku Yamashita, Tsuyoshi Inoue, Hirofumi Tsujino   +8 more
wiley   +1 more source

Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma. [PDF]

IJU Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

Dermatopathological Findings of an Erythema Multiforme-Like Drug Eruption During Enfortumab Vedotin Plus Pembrolizumab Therapy for Metastatic Urothelial Carcinoma: A Case Report. [PDF]

Clin Case Rep
Murofushi R, Kato Y, Seo T, Iwasaki K, Goto M, Monma N, Maekawa S, Obara W.   +7 more
europepmc   +1 more source

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source